IDEAYA, AstraZeneca launch IDE849-Imfinzi cancer study
IDEAYA Biosciences entered a clinical collaboration with AstraZeneca to test IDEAYA’s investigational DLL3 TOP1 antibody-drug conjugate IDE849 together with AstraZeneca’s PD-L1 inhibitor Imfinzi in extensive-stage small cell lung cancer.
Rhea-AI Filing Summary
IDEAYA Biosciences entered a clinical collaboration with AstraZeneca to test IDEAYA’s investigational DLL3 TOP1 antibody-drug conjugate IDE849 together with AstraZeneca’s PD-L1 inhibitor Imfinzi in extensive-stage small cell lung cancer.
IDEAYA will sponsor the combination study, while AstraZeneca supplies Imfinzi. IDEAYA is running a multi-site global Phase 1 clinical trial of IDE849 in DLL3 upregulated solid tumors, including small cell lung cancer, neuroendocrine carcinomas, neuroendocrine tumors, and melanoma, reflecting significant unmet medical need and the potential of DLL3 as a targeted therapy approach.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Terms
clinical collaboration agreement, antibody-drug conjugate, Phase 1 clinical trial, programmed death-ligand 1 (PD-L1) inhibitor, +2 more
6 terms
clinical collaboration agreement financial
"entered into a clinical collaboration agreement with AstraZeneca plc"
antibody-drug conjugate medical
"IDE849, the Company’s investigational, potential first-in-class DLL3 TOP1 antibody-drug conjugate"
An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.
Phase 1 clinical trial medical
"advancing a multi-site global Phase 1 clinical trial for IDE849"
A phase 1 clinical trial is the first stage of testing a new drug or treatment in people, typically involving a small group to assess safety, how the body handles the treatment, and appropriate dosing. For investors, phase 1 results are an early risk check — like a test drive that can reveal fatal flaws or promising signals — and they often cause big changes in a drug’s perceived value and the company’s prospects.
programmed death-ligand 1 (PD-L1) inhibitor medical
"Imfinzi® (durvalumab), a programmed death-ligand 1 (PD-L1) inhibitor"
extensive-stage small cell lung cancer medical
"in extensive-stage small cell lung cancer (“SCLC”)"
Extensive-stage small cell lung cancer is a fast-growing form of lung cancer that has spread beyond the original lung area to other parts of the chest or body. Because it is widespread at diagnosis, it usually requires systemic treatments like chemotherapy or immunotherapy rather than localized fixes, and has a more guarded outlook; for investors, that affects how big the market is for new drugs, trial designs, approval chances, and potential treatment costs.
neuroendocrine tumors medical
"including SCLC, neuroendocrine carcinomas (“NECs”), neuroendocrine tumors (“NETs”), and melanoma"
Neuroendocrine tumors are a type of abnormal growth that originates from cells responsible for releasing hormones into the bloodstream. These tumors can develop in various parts of the body and sometimes grow slowly or remain hidden for years. Their potential to affect hormone levels and spread makes them important for investors to monitor, especially as advancements in treatment may influence healthcare company performance.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What clinical collaboration did IDEAYA Biosciences (IDYA) announce with AstraZeneca?
IDEAYA Biosciences entered a clinical collaboration agreement with AstraZeneca to study IDE849 with AstraZeneca’s Imfinzi in extensive-stage small cell lung cancer. IDEAYA will sponsor the combination trial, while AstraZeneca will supply Imfinzi, aiming to evaluate safety and efficacy in this difficult-to-treat cancer.
What is IDE849 in the IDEAYA Biosciences (IDYA) and AstraZeneca study?
IDE849 is IDEAYA Biosciences’ investigational, potential first-in-class DLL3 TOP1 antibody-drug conjugate. It targets DLL3, which is reported to be upregulated in several solid tumor types, and is being evaluated for safety and efficacy in a global Phase 1 clinical trial program.
Which cancers are targeted in IDEAYA Biosciences’ IDE849 Phase 1 trial?
The IDE849 Phase 1 trial focuses on DLL3 upregulated solid tumors, including extensive-stage small cell lung cancer, neuroendocrine carcinomas, neuroendocrine tumors, and melanoma. These cancers have significant unmet medical need, and DLL3’s limited expression in normal tissues makes it a promising therapeutic target.
Who sponsors and supplies drugs in the IDEAYA (IDYA) and AstraZeneca collaboration?
IDEAYA Biosciences will sponsor the clinical combination study evaluating IDE849 with AstraZeneca’s Imfinzi. AstraZeneca will supply Imfinzi, a PD-L1 inhibitor, for the trial. This structure lets IDEAYA lead study operations while leveraging AstraZeneca’s established immunotherapy agent.
Where will IDEAYA Biosciences’ IDE849 clinical trial enroll patients?
IDEAYA’s multi-site global Phase 1 clinical trial for IDE849 plans to enroll patients across North America, Europe, Australia, South America, and Asia. This broad geographic footprint is designed to access diverse patient populations with DLL3 upregulated solid tumors, including small cell lung cancer.
AI-generated analysis. How Rhea-AI works. Not financial advice.
